ABB To Support Biotech Research In Ireland

ABB will provide expertise, technology and support to help advance the manufacturing of new biopharmaceutical medicines as part the recently announced $3.3 million Enterprise Ireland research program. The program’s goal is to deliver more efficient, reliable and cost-effective processes for manufacturing biopharmaceutical medicines.

Biopharmaceuticals are medical drugs produced using biotechnology; they are created through the alteration of molecules, genes and cells.

Ireland is the world’s largest net exporter of pharmaceuticals, with more than $23.7 billion worth shipped in 2008. Supported by the Irish government, the Enterprise Ireland research program will work with national and multinational Life Sciences companies and several universities to help develop next generation manufacturing practices and process improvements to support the continued growth and success of Ireland’s pharmaceutical industry.

The academic research team will be led by University College Dublin. xPAT, ABB’s PAT Data Management Solution, will form the cornerstone of the technology used in this project. ABB will also provide the expertise to help develop improved production practices and systems for biopharmaceutical manufacturing. These leading-edge process control and process analytical technology (PAT) developments will provide precise quality control throughout the manufacturing process, to monitor and improve product quality and raw material use in real-time, during production.

Daniel Keogh, ABB Sales Manager for PAT Solutions says, “This is a unique opportunity to work closely with the major life sciences corporations, to better understand their needs and clearly positions ABB as the leading global PAT solutions provider.”

“By the end of this research project, the biopharmaceutical sector in Ireland will be able to reduce costs, increase competitiveness, and produce more reliable data required by regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA),” said Enda Mimnagh, Life Sciences Manager, ABB Ireland.

For more information, visit: http://www.abb.com.

What are your comments?

Join the discussion today. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments